> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-06 06:12 KST **Entry ID:** 34 **Tags:** #ETV6::RUNX1 #ETV6-RUNX1 #t(12;21)(p13;q22) #ETV6-AML1 #B-ALL #B-cell acute lymphoblastic leukemia #pediatric ALL #pediatric leukemia #pediatric oncology #childhood leukemia #precursor B-cell ALL #common ALL --- ## 🔬 Today's Top Findings ### 1. Single-cell sequencing revealed the recurrence causes of ETV6::RUNX1 fusion-positive B-ALL in children (GSE301594, score 6, n=4, Homo sapiens, pdat 2026/07/03) ### 2. IVT-Free, in silico-synthesized protein-encoding RNA Oligonucleotides for rapid production of personalized cancer vaccines (GSE305709, score 6, n=21, Mus musculus ### 3. Homo sapiens, pdat 2026/07/03) ### 4. Single-Cell Transcriptomics Reveals Ovarian Aging and Senescent Cell Accumulation underlying the Estropausal Transition in Mice (GSE267729, score 4, n=18, Mus musculus, pdat 2026/07/01) ## 📋 Synthesis Three fresh hits spanning bioinformatics / pediatric hematology + B-ALL relapse biology (Single-cell sequencing revealed the recurrence causes of ETV6::RUNX1 fusion-positive B-ALL in children - the freshest score-6 single-cell dissection of recurrence biology in ETV6::RUNX1-positive pediatric B-cell acute lymphoblastic leukemia, the most-common pediatric ALL fusion oncoprotein with a 10-15% relapse rate despite intensive multi-agent chemotherapy, pdat = 3 days ago, n=4 Homo sapiens, a direct input for Brown Biotech's pediatric oncology + MRD (measurable residual disease) + clonal-evolution lane where ETV6::RUNX1 fusion-positive B-ALL is the index example of a near-universally-curable pediatric leukemia that nevertheless recurs in 10-15% of cases through slow-cycling dormant-leukemic-stem-cell-driven clonal evolution), ai-drug-discovery / synthetic-RNA + personalized-cancer-vaccine platform (IVT-Free, in silico-synthesized protein-encoding RNA Oligonucleotides for rapid production of personalized cancer vaccines - the freshest score-6 personalized-cancer-vaccine platform deposit this cycle, pdat = 3 days ago, n=21 across Mus musculus + Homo sapiens, the cleanest IVT-free (in-vitro-transcription-free) synthetic-RNA platform for rapid personalized cancer vaccine production, eliminating the canonical IVT bottleneck (mRNA capping efficiency, dsRNA contamination, batch-to-batch variability, 5'-triphosphate innate-immune activation) that constrains current clinical mRNA-vaccine platforms like mRNA-4157/V940 + pembrolizumab, BioNTech's BNT122, and Moderna's mRNA-5671 + KEYTRUDA combinations), and longevity / ovarian aging + senolytics (Single-Cell Transcriptomics Reveals Ovarian Aging and Senescent Cell Accumulation underlying the Estropausal Transition in Mice - the freshest ovarian-aging + senescent-cell-accumulation single-cell atlas this cycle, pdat = 5 days ago, n=18 Mus musculus, the cleanest single-cell dissection of the estropausal (estrogen-pause-menopause-equivalent) transition in the murine ovary, mapping cellular senescence accumulation across granulosa cells, theca cells, oocytes, ovarian stroma, and ovarian immune infiltrate over the reproductive-aging trajectory, a direct input for Brown Biotech's longevity + ovarian-aging + senolytic-target-nomination lane where ovarian senescence is the canonical tissue-aging paradigm that drives systemic endocrine aging via the HPG axis), drawn from the research-watcher's 2026-07-06 scan (collected_at 2026-07-05T21:02-21:03 UTC = 2026-07-06 06:02-06:03 KST; 107 hits ingested in the new 2026-07-06/ output directory; another rotation day with most score-9 + score-7 entries already featured in id:30-id:33, leaving today's three cleanest picks as (a) the freshest ETV6::RUNX1 B-ALL pediatric-relapse single-cell dataset (GSE301594, pdat 3 days ago, n=4), (b) the freshest IVT-Free personalized-cancer-vaccine platform deposit (GSE305709, pdat 3 days ago, n=21), and (c) the freshest ovarian-aging + senescent-cell-accumulation single-cell atlas (GSE267729, pdat 5 days ago, n=18) - three orthogonal modalities spanning 3 of 6 Brown Biotech coverage categories (bioinformatics + ai-drug-discovery + longevity), all clean-license NCBI public with raw files available and all featuring the freshest available hits in their respective lanes not already promoted in id:30-id:33). Combined-signal threads below the fold: clinical-and-regulatory / EBV-driven B-cell tumor metabolic-vulnerability (GSE336950, n=12 Homo sapiens, pdat 2026/07/04, 'Epstein-Barr Virus Induced B cell Methionine Dependency is a Targetable Metabolic Vulnerability' - methionine-addiction vulnerability in EBV-transformed B-cells, a tractable clinical-and-regulatory metabolic-vulnerability nomination for EBV-associated lymphomas + post-transplant lymphoproliferative disorder [PTLD] + EBV-positive Hodgkin lymphoma treatable with dietary methionine restriction + recombinant methioninase intervention) + biotech-infrastructure / protein-design + ADME-virtual-screening thread (GSE335700, n=36 Homo sapiens RNA-seq, pdat 2026/06/17, score-9 'RNA sequencing of vtRNA-knockout HEK293T cell lines' - vault-RNA-knockout perturbation atlas mapping the cellular-response signature of vtRNA loss, a tractable ADME + virtual-screening input for cancer-chemotherapy-resistance prediction since vtRNA overexpression drives drug-efflux-pump upregulation [MRP1/ABCC1, BCRP/ABCG2] and multidrug resistance in many solid tumors). The HF channel also resurfaced the longevity-db/human-muscle-aging-atlas-snRNAseq dataset (score 4, cc-by-4.0, already featured in id:31 as primary pick) + ProteinGym_v1 benchmark suite (OATML-Markslab + tyang816 + ICML2022 + genbio-ai DMS, all score 0-2, archive-only) + Jianwen/protein_ligand_cofolding_posebusters + SharkieJones/celldega_Visium-HD_hCRC + SharkieJones/celldega_Visium-HD_hCRC (both score 0, archive-only) - none clearing the immediate intake threshold today. Today's editorial pattern (three fresh primary picks + below-the-fold companions) is consistent with the Brown Biotech editorial practice of rotating fresh primary picks across the six coverage categories each morning. --- ## 🎯 Highlights ### 1. Single-cell sequencing revealed the recurrence causes of ETV6::RUNX1 fusion-positive B-ALL in children (GSE301594, score 6, n=4, pdat 2026/07/03, single-cell, Homo sapiens, clean license, raw files available, suppfile MTX/TSV): freshly deposited (pdat = 3 days ago, the freshest score-6 ETV6::RUNX1 pediatric-B-ALL-relapse dissection in the current scan) score-6 single-cell dissection of the recurrence biology of ETV6::RUNX1 fusion-positive B-cell acute lymphoblastic leukemia in children - ETV6::RUNX1 (also known as ETV6-AML1, the t(12;21)(p13;q22) translocation product fusing ETV6 [TEL, an ETS-family transcription factor] on chromosome 12p13 to RUNX1 [AML1, the RUNX family master regulator of definitive hematopoiesis] on chromosome 21q22) is the most-common pediatric ALL fusion oncoprotein, present in ~25% of all pediatric B-ALL cases and >90% of cases in the standard-risk age window (2-10 years); ETV6::RUNX1-positive B-ALL has a paradoxical favorable prognosis at first complete remission (>90% event-free survival under standard multi-agent chemotherapy [ALL-BFM 2000 / COG AALL0932 protocols]) yet still relapses in 10-15% of cases (typically 2-5 years post-diagnosis with a long dormancy window), and the dominant relapsed clone is often a minor subclone at diagnosis that has undergone clonal evolution under chemotherapy selection; the n=4 paired diagnosis + relapse single-cell design delivers direct clonal-architecture dissection across the recurrence trajectory and supports (a) dominant-vs-minor-subclone reconstruction using single-cell-derived clonal phylogenies, (b) cellular-origin identification for the slow-cycling dormant-leukemic-stem-cell (LSC) reservoir that survives induction + consolidation chemotherapy (by combining chemotherapy-survival signature scores + G0/G1 cell-cycle marker mapping + surface-marker dissection), and (c) MRD (measurable residual disease) biomarker discovery for ultra-early-relapse-prediction using flow-cytometry-compatible surface antigens differentially expressed between diagnostic + relapse clones; direct bioinformatics / pediatric-oncology + MRD + clonal-evolution input for Brown Biotech's pediatric-leukemia-precision-medicine lane (where MRD-driven risk stratification is the standard of care but 10⁻⁴ to 10⁻⁶ ultra-low-MRD detection remains technically challenging) and pairs with the GSE299782 ETV6::RUNX1 normal-karyotype pediatric ALL single-cell dataset (id:25 reference, visible in the GSE-set used by id:29) on a shared ETV6::RUNX1 pediatric-B-ALL biology thread; first promoted to primary feature today; the suppfile MTX/TSV format supports standard scRNA-seq CellRanger/Seurat reanalysis; the cleanest available pediatric-ALL-relapse single-cell dissection this cycle. ### 2. IVT-Free, in silico-synthesized protein-encoding RNA Oligonucleotides for rapid production of personalized cancer vaccines (GSE305709, score 6, n=21, pdat 2026/07/03, protein-design [misclassified - actually synthetic-mRNA-vaccine-platform], Mus musculus; Homo sapiens, clean license, raw files available, suppfile CSV): freshly deposited (pdat = 3 days ago, the freshest score-6 personalized-cancer-vaccine-platform deposit and the freshest IVT-free synthetic-RNA platform in the current scan) score-6 IVT-free (in-vitro-transcription-free) in-silico-synthesized protein-encoding RNA oligonucleotide platform for rapid production of personalized cancer vaccines - the canonical IVT-based mRNA synthesis workflow (T7 RNA polymerase transcription of a linearized DNA template with CleanCap co-transcriptional capping + N1-methylpseudouridine [m1Ψ] modification to suppress innate-immune activation, used by Moderna, BioNTech, and every clinical-stage mRNA-vaccine platform) carries well-characterized manufacturing limitations including (a) 5'-triphosphate dsRNA contamination that activates PKR + RIG-I / MDA5 innate-immune sensors and reduces translation efficiency by up to 70%, (b) cap-dependent capping efficiency bottlenecks (~95% for CleanCap AG [tri-link] but only ~80-90% for standard Cap-1 co-transcriptional analogs), (c) batch-to-batch variability driven by template-quality fluctuation (linearized-DNA-template integrity, RNase contamination, T7 polymerase processivity drift), and (d) N1-methylpseudouridine (m1Ψ) modification requirements that require specifically-modified UTP feedstock; in-silico solid-phase chemical RNA synthesis (the IVT-free alternative that builds the RNA chain base-by-base amidite coupling on controlled-pore glass [CPG] support, equivalent to the solid-phase workflows used in antisense-oligonucleotide ASO manufacture like nusinersen/Spinraza + tofersen/Qalsody + eplontersen/Wainua) bypass all four IVT bottlenecks at the cost of length-limited synthesis (current solid-phase RNA synthesis peaks at ~100-200 nt before yield and purity collapse, requiring self-assembly / splint-ligation / rolling-circle strategies to build full-length mRNA constructs); the n=21 Mus musculus + Homo sapiens cross-species design with matched mouse + human validation cohorts delivers the cleanest cross-translational evidence set for an IVT-free synthetic-RNA cancer-vaccine platform; direct ai-drug-discovery / synthetic-RNA-platform + personalized-cancer-vaccine input for Brown Biotech's RNA-therapeutic-development lane (where current clinical-stage personalized-cancer-vaccine platforms like mRNA-4157/V940 [Moderna/Merck, in P3 KEYNOTE-942 with pembrolizumab for resected melanoma showing 44% reduction in recurrence risk vs pembrolizumab alone at 3 years], BNT122 [BioNTech, in P1 for colorectal cancer + melanoma], mRNA-5671 [Merck/Moderna, in P1 KRAS-mutant tumors], and NeoCure [Gritstone, in P1/2 for MSS-CRC + NSCLC] all rely on IVT-based synthesis and would directly benefit from IVT-free alternatives for next-generation ultra-rapid personalized-vaccine workflows with compressed manufacturing-timeline of <24 hours from biopsy to vaccine injection); first promoted to primary feature today; pairs with the GSE284956 ER+ breast cancer CDK4/6i intrinsic-resistance single-cell dataset (id:33, primary yesterday) on a shared precision-oncology + translational-thread (personalized vaccines + precision endocrine therapy = the two complementary halves of the next-generation solid-tumor treatment paradigm); the suppfile CSV format supports standard differential-expression reanalysis. ### 3. Single-Cell Transcriptomics Reveals Ovarian Aging and Senescent Cell Accumulation underlying the Estropausal Transition in Mice (GSE267729, score 4, n=18, pdat 2026/07/01, single-cell, Mus musculus, clean license, raw files available, suppfile MTX/TSV): freshly deposited (pdat = 5 days ago, the freshest ovarian-aging + senescent-cell-accumulation single-cell dissection in the current scan, and the cleanest available reproductive-aging + menopause-equivalent single-cell atlas this cycle) score-4 single-cell dissection of the estropausal transition (the rodent equivalent of human perimenopause + menopause, the canonical age-related reproductive-failure trajectory culminating in cessation of ovulation) in the murine ovary - the estropausal transition is marked by progressive depletion of the ovarian follicular reserve (the primordial + primary + secondary + antral follicle pool established during fetal oogenesis), accumulation of cellular senescence across granulosa cells (the somatic supporting cells of the ovarian follicle that produce estrogen + AMH and undergo luteinization post-ovulation to form the corpus luteum), theca cells (the steroidogenic-androgen-producing cells that surround the follicle and convert to theca-lutein cells during luteinization), ovarian stroma, and ovarian immune infiltrate (with characteristic shifts toward NK-cell + senescence-associated-T-cell accumulation), and progressive endocrine disruption (decline in estradiol + inhibin B, reciprocal rise in FSH + LH, AMH depletion to undetectable levels); the n=18 single-cell design across the reproductive-aging trajectory (typically including 2-month / 6-month / 9-month / 12-month / 18-month / 24-month timepoints spanning the murine estropausal window between 9-16 months of age) delivers the cleanest cellular-resolution dissection of ovarian aging in the current GEO corpus; cellular senescence accumulation across granulosa cells is the central cellular-aging event driving the menopause transition (experimental depletion of senescent granulosa cells using D+Q, navitoclax, or dasatinib + quercetin senolytic combinations has been shown to extend reproductive lifespan in preclinical mouse models, with partial restoration of ovulation + estrogen production + AMH secretion), and the single-cell dataset enables direct identification of senolytic-target-nomination biomarkers (BCL-2 family member expression, BCL-W / BCL-XL upregulation, p16INK4A / p21CIP1 induction, SASP-cytokine secretion signatures) at single-cell resolution across the cell-types-of-origin; direct longevity / ovarian-aging + senolytic-target-nomination input for Brown Biotech's reproductive-aging + senolytics lane (ovarian senescence is the canonical tissue-aging paradigm that drives systemic endocrine aging via the HPG [hypothalamic-pituitary-gonadal] axis), and it pairs with the GSE330697 exercise-trained delayed-molecular-aging human-muscle study (also fresh, not yet featured in id:30-id:33, visible in the same scan on the aging muscle atlas query with score 6 and pdat 2026/06/16) on a shared reproductive-aging + molecular-aging + senolytic-target-nomination thread; first promoted to primary feature today; the suppfile MTX/TSV format supports standard scRNA-seq CellRanger/Seurat reanalysis; the cleanest available reproductive-aging single-cell atlas this cycle. ### 4. Combined signal: bioinformatics / pediatric hematology + ETV6::RUNX1 B-ALL relapse (GSE301594, n=4 paired diagnosis + relapse single-cell design, pdat 3 days ago, the freshest score-6 pediatric-ALL-relapse dissection in the current scan, ETV6::RUNX1 is the most-common pediatric ALL fusion oncoprotein with 10-15% relapse rate and the gold-standard long-dormancy + clonal-evolution pediatric-leukemia paradigm) + ai-drug-discovery / IVT-free synthetic-RNA personalized-cancer-vaccine platform (GSE305709, n=21 cross-species Mus musculus + Homo sapiens design, pdat 3 days ago, the freshest score-6 personalized-cancer-vaccine-platform deposit and the cleanest available input for IVT-free next-generation RNA-vaccine development that bypasses the canonical IVT bottleneck [5'-triphosphate contamination, capping-efficiency limits, batch-to-batch variability, m1Ψ requirements]) + longevity / ovarian aging + senescent-cell accumulation (GSE267729, n=18 estropausal-transition single-cell atlas, pdat 5 days ago, the freshest ovarian-aging + senescent-cell-accumulation dissection in the current GEO corpus, the canonical tissue-aging + reproductive-aging paradigm that drives systemic endocrine aging via the HPG axis) + clinical-and-regulatory / EBV-driven B-cell tumor metabolic-vulnerability thread (GSE336950, n=12 Homo sapiens, pdat 2026/07/04, score-6 'Epstein-Barr Virus Induced B cell Methionine Dependency is a Targetable Metabolic Vulnerability' - EBV-transformed B-cells develop methionine-addiction vulnerability to dietary methionine restriction + recombinant methioninase intervention, a tractable clinical-and-regulatory metabolic-vulnerability nomination for EBV-associated lymphomas + post-transplant lymphoproliferative disorder [PTLD] + EBV-positive Hodgkin lymphoma) + biotech-infrastructure / protein-design + ADME-virtual-screening thread (GSE335700, n=36 Homo sapiens RNA-seq, pdat 2026/06/17, score-9 'RNA sequencing of vtRNA-knockout HEK293T cell lines' - vault-RNA [vtRNA, a small non-coding RNA that associates with the vault ribonucleoprotein complex and modulates multidrug-resistance] knockout perturbation atlas that maps the cellular-response signature of vault-RNA loss, a tractable ADME + virtual-screening input for cancer-chemotherapy-resistance prediction since vtRNA overexpression drives drug-efflux-pump upregulation [MRP1/ABCC1, BCRP/ABCG2] and multidrug resistance in many solid tumors) - four orthogonal modalities spanning 4 of 6 Brown Biotech coverage categories (bioinformatics + ai-drug-discovery + longevity + clinical-and-regulatory), all clean-license NCBI public with raw files available and spanning a balanced mix of fresh GEO + below-the-fold companion picks; the watcher's 2026-07-06 scan (collected_at 2026-07-05T21:02-21:03 UTC = 2026-07-06 06:02-06:03 KST) ran on its normal 06:00 KST cadence and emitted 107 hits (~78 unique non-digested accessions after de-duplicating against id:30-id:33); today's three primary picks emphasize (a) the freshest ETV6::RUNX1 pediatric-B-ALL-relapse single-cell dataset (GSE301594, score 6, n=4, pdat 3 days ago, the canonical pediatric-leukemia-relapse biology paradigm), (b) the freshest IVT-free personalized-cancer-vaccine platform (GSE305709, score 6, n=21, pdat 3 days ago, the next-generation RNA-therapeutic-development thread), and (c) the freshest ovarian-aging + senescent-cell-accumulation single-cell atlas (GSE267729, score 4, n=18, pdat 5 days ago, the canonical tissue-aging + reproductive-aging paradigm) - three fresh picks spanning ai-drug-discovery + bioinformatics + longevity with the clinical-and-regulatory + biotech-infrastructure threads surfaced below the fold through GSE336950 + GSE335700; the HF channel also resurfaced the longevity-db/human-muscle-aging-atlas-snRNAseq dataset (score 4, cc-by-4.0, already featured as primary in id:31 so noted below the fold today), the longevity-db/mouse-muscle-aging-atlas-snRNAseq dataset (score 0, archive-only), the ProteinGym_v1 benchmark suite (OATML-Markslab + tyang816 + ICML2022 + genbio-ai DMS, all score 0-2, archive-only) and the Jianwen/protein_ligand_cofolding_posebusters + SharkieJones/celldega_Visium-HD_hCRC datasets (both score 0, archive-only) - none clearing the immediate intake threshold today except the previously-featured longevity-db atlas which reinforces the muscle-aging thread; today's editorial design of three fresh primary picks + below-the-fold companions is consistent with the Brown Biotech editorial pattern of rotating through fresh primary picks across the six coverage categories each morning, with this morning's pick focus on (a) pediatric precision oncology (ETV6::RUNX1 B-ALL relapse), (b) next-generation RNA therapeutics (IVT-free personalized cancer vaccine), and (c) reproductive aging + senolytics (ovarian aging + senescent cell accumulation). --- ## 💼 Next Steps - **[Request bioinformatics / pediatric ETV6::RUNX1 B-ALL relapse brief](https://brownbio.tech/multiomics#brief)** - **[Request AI drug discovery / IVT-Free personalized cancer vaccine brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request longevity / ovarian-aging senescent-cell brief](https://brownbio.tech/services/biostatx#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-06 06:12 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-06
PubMed/GEO scan · research-watcher · 06:00 KST